KalVista reports Q2 EPS (80c), consensus (79c)

Cash, cash equivalents and marketable securities were $103.2M as of October 31, 2023, vs. $149.4M as of April 30, 2023. The decrease in the net cash and marketable securities position was due to cash consumption from operating expenses.. “We are in the process of completing the KONFIDENT trial and we look forward to advancing sebetralstat for a NDA submission in the first half of 2024,” said CEO Andrew Crockett. “As we plan on several regulatory filings in the coming year, we are also continuing to build out our commercial organization in order to support a rapid launch upon FDA approval.”